Artivion (AORT) Earnings Analysis
Artivion (AORT) next reports earnings on 2026-08-06, consensus EPS 0.0088 USD. Last quarter (2026-05-07) it missed with EPS 0.03 USD vs 0.06 USD est (-50%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E 100.28.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does AORT next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 0.0088 USD |
| Revenue estimate | 0.12B |
AORT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.03 USD | 0.06 USD | -50% | Miss |
| 2026-02-12 | 0.17 USD | 0.14 USD | +21.4% | Beat |
| 2025-11-06 | 0.16 USD | 0.14 USD | +14.3% | Beat |
| 2025-08-07 | 0.24 USD | 0.11 USD | +118.2% | Beat |
| 2025-05-05 | 0.06 USD | 0.12 USD | -50% | Miss |
| 2025-02-24 | -0.39 USD | 0.12 USD | -425% | Miss |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
AORT valuation and analyst view
| Trailing P/E | 100.28 |
|---|---|
| Trailing EPS | 0.24317 USD |
| Price / book | 2.68 |
| Dividend yield | 0.00% |
| Market cap | 1.22B |
| Analyst consensus | Buy (10 buy / 2 hold / 0 sell) |
| Avg price target | 40.5 USD |
Related research pages
Frequently asked questions
When is Artivion (AORT)'s next earnings date?
Artivion is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.0088 USD and revenue estimate of 0.12B.
Did AORT beat earnings last quarter?
In its 2026-05-07 report, AORT posted EPS of 0.03 USD versus a 0.06 USD estimate — a miss of 50%.
What is AORT's earnings track record?
Over the last 6 reported quarters with consensus data, AORT beat estimates 3 times (50%).
What is AORT's current P/E ratio and EPS?
AORT trades at a trailing P/E of 100.28 on trailing EPS of 0.24316678454050006 USD.
What do analysts rate AORT?
Analyst consensus is "Buy" across 12 ratings (0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 40.5 USD.